524
Views
23
CrossRef citations to date
0
Altmetric
Drug Evaluation

Oxytrex®: an oxycodone and ultra-low-dose naltrexone formulation

Pages 1277-1283 | Published online: 09 Aug 2007

Bibliography

  • CRAIN SM, SHEN KF: Opioids can evoke direct receptor-mediated excitatory effects on sensory neurons. Trends Pharmacol. Sci. (1990) 11(2):77-81.
  • CRUCIANI RA, LUSSIER D, MILLER-SAULTZ D, ARBUCK DM: Ultra-low dose oral naltrexone decreases side effects and potentiates the effect of methadone. J. Pain Symp. Manage (2003) 25(6):491-494.
  • WANG HY, FRIEDMAN E, OLMSTEAD MC, BURNS LH: Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in μ opioid receptor-G protein coupling and G-βγ signaling. Neuroscience (2005) 135(1):247-261.
  • CRAIN SM, SHEN KF: Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability. Pain (2000) 84(2-3):121-131.
  • WANG HY, BURNS LH: G-βγ that interacts with adenylyl cyclase in opioid tolerance originates from a Gs protein. J. Neurobiol. (2006) 66(12):1302-1310.
  • CHINDALORE VL, CRAVEN RA, YU KP, BUTERA PG, BURNS LH, FRIEDMANN LH: Adding ultra-low dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized controlled trial of Oxytrex. J. Pain (2005) 6(6):392-399.
  • WEBSTER LR, BUTERA PG, MORAN LV, WU N, BURNS LH, FRIEDMANN N: Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain. J. Pain (2006) 7(12):937-946.
  • SPIERINGS EL, BUTERA PG, WU N, MORAN LV, FRIEDMANN N: Phase III study to assess physical dependence and analgesic efficacy of Oxytrex versus oxycodone. Presented at the 25th Annual Scientific Meeting of the American Pain Society. San Antonio, Texas, USA (4 – 5 May 2006). Poster 814.
  • OLMSTEAD MC, BURNS LH: Ultra-low-dose naltrexone suppresses rewarding effects of opiates and aversive effects of opiate withdrawal in rats. Psychopharmacology (2005) 181(3):576-581.
  • LERI F, BURNS LH: Ultra-low-dose naltrexone reduces the rewarding potency of oxycodone and relapse vulnerability in rats. Pharmacol. Biochem. Behav. (2005) 82(2):252-262.
  • AGRAWAL YP: Low dose naltrexone therapy in multiple sclerosis. Med. Hypotheses (2005) 64(4):721-724.
  • LIU B, GAO HM, WANG JY, JEOHN GH, COOPER CL, HONG JS: Role of nitric oxide in inflammation-mediated neurodegeneration. Ann. NY Acad. Sci. (2002) 962:318-331.
  • BURNS LH: Ultra-low-dose opioid antagonists enhance opioid analgesia while reducing tolerance, dependence and addictive properties. In: Recent Developments in Pain Research. Capasso A (Ed.). Kerala, India: Research Signpost (2005):115-136.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.